SOPHiA GENETICS SA (SOPH) chair trades 44,381 shares under 10b5-1 plan
Rhea-AI Filing Summary
SOPHiA GENETICS SA Executive Chairman and director Jurgi Camblong reported option exercises and share sales executed pursuant to a duly adopted Rule 10b5-1(c) trading plan. On July 20, 2026, he exercised options for 4,581 ordinary shares at $3.16 per share and sold 4,581 shares at a weighted average $6.1654, in multiple trades between $6.10 and $6.20, plus 19,800 shares at a weighted average $6.3233, in trades between $6.30 and $6.37. On July 21, 2026, he sold 20,000 ordinary shares at a weighted average $6.6327, in trades between $6.60 and $6.72. A footnote states he continues to hold 4,641,476 derivative share options across remaining grant tranches.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
5 txns
Insider
Camblong Jurgi
Role
Executive Chairman
Sold
44,381 shs ($286K)
Approx. gross sale proceeds
$286K
Approx. exercise cost
$14K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares F1, F4 | 20,000 | $6.6327 | $133K |
| Exercise | Share Option (Right to Buy) F5, F6 | 4,581 | $0.00 | $0.00 |
| Sale | Ordinary Shares F1, F2 | 19,800 | $6.3233 | $125K |
| Exercise | Ordinary Shares F1 | 4,581 | $3.16 | $14K |
| Sale | Ordinary Shares F1, F3 | 4,581 | $6.1654 | $28K |
Holdings After Transaction:
Share Option (Right to Buy) — 0 shares (Direct);
Ordinary Shares — 3,492,822 shares (Direct)
Footnotes (6)
- F1. Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.30 to $6.37, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.10 to $6.20, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.60 to $6.72, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The share options are fully vested and exercisable.
- F6. Following the transaction reported on this line, the Reporting Person holds an aggregate total of 4,641,476 derivative share options across all remaining grant tranches with varying exercise prices.
Key Figures
Total shares sold: 44,381 shares
Option shares exercised: 4,581 shares
Option exercise price: $3.16 per share
+4 more
7 metrics
Total shares sold
44,381 shares
Aggregate ordinary-share sales reported across all sale transactions in this Form 4
Option shares exercised
4,581 shares
Ordinary shares acquired via option exercise on July 20, 2026
Option exercise price
$3.16 per share
Conversion or exercise price of the share option exercised on July 20, 2026
Sale price for 19,800 shares
$6.3233 per share
Weighted average price for 19,800 ordinary shares sold on July 20, 2026
Sale price for 4,581 shares
$6.1654 per share
Weighted average price for 4,581 ordinary shares sold on July 20, 2026
Sale price for 20,000 shares
$6.6327 per share
Weighted average price for 20,000 ordinary shares sold on July 21, 2026
Remaining derivative options
4,641,476 options
Aggregate derivative share options held after the reported transactions
Key Terms
Rule 10b5-1(c), weighted average price, derivative share options
3 terms
Rule 10b5-1(c) regulatory
"Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c)."
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did SOPHiA GENETICS (SOPH) report for July 20, 2026?
On July 20, 2026, Executive Chairman Jurgi Camblong exercised options for 4,581 shares at $3.16 and sold 4,581 shares at $6.1654 plus 19,800 shares at $6.3233, all in multiple trades within disclosed price ranges under a Rule 10b5-1(c) plan.
What additional SOPHiA GENETICS (SOPH) insider sale occurred on July 21, 2026?
On July 21, 2026, Jurgi Camblong sold 20,000 ordinary shares of SOPHiA GENETICS at a weighted average price of $6.6327, executed in multiple trades at prices ranging from $6.60 to $6.72, as disclosed in the Form 4 footnote.
Were the SOPHiA GENETICS (SOPH) insider trades made under a Rule 10b5-1 plan?
Yes. A checkbox and footnote state the transactions were made pursuant to a duly adopted Rule 10b5-1(c) trading plan, indicating the trades followed a pre-established instruction rather than being discretionary at the time of execution.
How many derivative options does Jurgi Camblong still hold in SOPHiA GENETICS (SOPH)?
After the reported option exercise, a footnote states that Jurgi Camblong holds an aggregate total of 4,641,476 derivative share options across all remaining grant tranches, each with varying exercise prices, indicating substantial remaining option-based exposure.
What options did the SOPHiA GENETICS (SOPH) Executive Chairman exercise in this Form 4?
He exercised a fully vested share option covering 4,581 ordinary shares at an exercise price of $3.16 per share, eliminating that specific option tranche (0 options remaining in that grant) and converting it into ordinary shares that were then sold.